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Abstract
Background: The 3398delAAAAG mutation in BRCA2 was recently found to recur in breast and/
or ovarian cancer families from the French Canadian population of Quebec, a population that has
genetic attributes consistent with a founder effect. To characterize the contribution of this
mutation in this population, this study established the frequency of this mutation in breast and
ovarian cancer cases unselected for family history of cancer, and determined if mutation carriers
shared a common ancestry.
Methods: The frequency was estimated by assaying the mutation in series of French Canadian
breast cancer cases diagnosed before age 41 (n = 60) or 80 (n = 127) years of age, and ovarian
cancer cases (n = 80) unselected for family history of cancer by mutation analysis. Haplotype
analysis was performed to determine if mutation carriers shared a common ancestry. Members
from 11 families were analyzed using six polymorphic microsatellite markers (cen-D13S260-
D13S1699-D13S1698-D13S1697-D13S1701-D13S171-tel) spanning approximately a 3.6 cM
interval at the chromosomal region 13q13.1, which contains BRCA2. Allele frequencies were
estimated by genotyping 47 unaffected female individuals derived from the same population.
Haplotype reconstruction of unaffected individuals was performed using the program PHASE.
Results: The recurrent BRCA2 mutation occurred in 1 of 60 (1.7%) women diagnosed with breast
cancer before 41 years of age and one of 80 (1.3%) women with ovarian cancer. No mutation
carriers were identified in the series of breast cancer cases diagnosed before age 80. Mutation
carriers harboured one of two haplotypes, 7-3-9-3 – [3/4]-7, that varied with marker D13S1701
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marker located approximately 0.3 cM distal to D13S171, did not favour a genetic recombination
event to account for the differences in D13S1701 alleles within the haplotype. Although mutation
carriers harbour genotypes that are frequent in the French Canadian population, neither mutation-
associated haplotype was plausible in reconstructed haplotypes of 47 individuals of French
Canadian descent.
Conclusion: These results suggest that mutation carriers share a related ancestry; further
supporting the concept that recurrent BRCA1 and BRCA2 mutations in the French Canadian
population could be attributed to common founders. This finding provides further support for
targeted screening of recurrent mutations in this population before large-scale mutation analyses
are performed.
Background
A significant proportion of breast and/or ovarian cancer
families of French Canadian descent harbour specific
recurrent mutations in BRCA1 and BRCA2 [1] which con-
fer a significantly increased lifetime risk of developing
young age of onset breast cancer and ovarian cancer [2-5].
The most common mutations were 4446C>T and
2953delGTAinsC in BRCA1 and, 6085G>T and
8765delAG in BRCA2. Haplotype analyses of polymor-
phic microsatellite repeat markers located within and
flanking these cancer susceptibility genes have suggested
that carriers of the same mutation share a common ances-
try [1,6]. Previous analyses of French Canadian popula-
tion have also shown that these recurrent BRCA1 and
BRCA2 mutations accounted for about 13% (diagnosis
before age 41 years) and 3% (diagnosis before 80 years of
age) of breast cancer cases and 8% of ovarian cancer cases
[7-9]. Recently, we reported a new BRCA2 mutation,
3398delAAAAG, found to occur in four of 169 unrelated
breast and/or ovarian families of French Canadian
descent [10]. A mutational screen consisting of the most
common mutations, 4446C>T and 2953delGTAinsC in
BRCA1 and, 6085G>T and 8765delAG in BRCA2, and
3398delAAAAG accounted for 62 of 74 (84%) mutation-
positive French Canadian families with at least three cases
of breast cancer (diagnosed before 66 years of age) and/or
ovarian cancer. Based on these findings it was proposed
that an initial screen for BRCA mutations in high risk fam-
ilies in this population include the new recurrent BRCA2
mutation [10].
To further characterize the contribution of this recently
identified recurrent mutation in the French Canadian
population, we estimated its frequency in breast and ovar-
ian cancer cases unselected for family history of cancer.
Given the precedence of the founder effect in this popula-
tion, we also determined if carriers of the 3398delAAAAG
mutation harbor a common haplotype that would suggest
a shared ancestry.
Methods
Study population and mutation analyses
Three independently ascertained series of breast cancer
and ovarian cancer cases unselected for family history of
cancer were used to estimate the frequency of the BRCA2
mutation 3398delAAAAG. The breast cancer cases
included a series of women diagnosed with cancer before
41 years of age (n = 60), and an independently ascertained
series of women diagnosed with breast cancer before 80
years of age (n = 127). The ovarian cancer cases include a
series of women (n = 80) diagnosed with invasive epithe-
lial ovarian cancers ascertained with no age restriction. All
women reported French Canadian ancestry and the cases
have been described elsewhere [7-9]. The analysis for the
presence of the BRCA2 3398delAAAAG mutation was per-
formed on DNA extracted from peripheral blood lym-
phocytes of the breast or ovarian cancer cases as described
previously [10].
Eleven index cases harbouring the 3398delAAAAG muta-
tion affected with breast and/or ovarian cancer (Table 1)
and, where possible, members from their families were
genotyped for markers flanking BRCA2. Four of the eleven
families (636, 762, 859 and 937) were reported previ-
ously [10]. The remaining seven families (1429, 1430,
1441, 1448, 1450, 1454, and 1458) were obtained from
the Hereditary Cancer Clinics of McGill University and
the Breast Clinic of the Division de gynécologie
oncologique, Notre-Dame Hospital in Montreal. These
two clinics represent the major genetic testing and coun-
selling centres in the Province of Quebec and the only
referring centres for Montreal and nearby regions. To our
knowledge this study contains all known cases/families
that harbour the BRCA2 3398delAAAAG mutation. The
cancer site (breast or ovarian cancer) and age of diagnosis
of the index case for genotype analysis in each family and
those of relatives within three-degree relationships of the
index case are shown in Table 1. Additional family mem-
bers for phasing haplotypes were not available for families
1429 and 1430. The families harbouring the same muta-
tion are not related to one another based on similarity ofPage 2 of 7
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reported French Canadian ancestry.
Genotyping assays and haplotyping analysis
Genotype analysis was performed using seven polymor-
phic microsatellite repeat markers flanking BRCA2:
D13S260, D13S1699, D13S1698, D13S1697, D13S1701,
D13S171, and D13S1695. The order of the markers [11]
and distances relative to each other and BRCA2 [12] are
shown in Table 2. Genomic DNA from peripheral blood
lymphocytes from index cases and family members were
genotyped essentially as described previously [1,6].
Briefly, the PCR assays were performed in 12.5 ul volumes
containing 50 ng genomic DNA; 1 × PCR buffer (Invitro-
gen); 200 uM of each dCTP, dGTP and dTTP; 10 uM dATP;
50 pmol of each primer [1]; 1.25 uCi 35S-dATP; and 0.5 U
Taq DNA polymerase (Invitrogen). The reactions were
amplified in a Perkin-Elmer 9600 Thermal Cycler for a
total of 35 cycles at 95°C for 15 s, annealing at 55°C for
15 s, and 72°C for 30 s. The PCR products were diluted
10-fold with loading buffer (90% formamide, 10 mM
EDTA pH8.0, 0.05% bromophenol blue, 0.05% xylene
cyanol), denatured at 95°C for 5 min, and then 4 ul was
loaded on a 5% acrylamide gel. The samples were electro-
phoresed at 70 W constant power at room temperature,
transferred to Whatman paper, dried at 80°C on a vacuum
gel drier, and then autoradiographed (Kodak) for 48–72
hours. The disease allele-associated haplotype was
deduced by inspection of segregating genotypes in the
families. The frequency of alleles was estimated by geno-
typing the 11 index cases representing an affected individ-
ual from each independently ascertained family
harbouring the mutation and at least 47 unrelated, non-
mutation carrier participants of French Canadian descent
that were not affected with cancer.
Haplotype reconstruction
The genotypes of 47 French Canadians unaffected with
cancer were used to reconstruct haplotypes that were not
associated with BRCA2 mutation carriers. Haplotypes
were reconstructed using the program PHASE version 2.1
[13,14] based on genotypes deduced from the analysis of
the six microsatellite markers: D13S260, D13S1699,
D13S1698, D13S1697, D13S1701, and D13S171. The
physical distances of the genetic markers required for hap-
lotype reconstruction were derived from the Human
Genome Browser assembly hg17 (May 2004 version)
from the UCSC Genome Bioinformatics [15].
Results and discussion
Haplotype analysis was initiated with six polymorphic
markers, D13S260, D13S1699, D13S1698, D13S1697,
Table 1: Family history of cancer in 3398delAAAAG BRCA2 mutation carriers
Family Number Cancer site(s) and age of diagnosis 
of index case
Family history of breast and 
ovarian cancers and age at 
diagnosis of affected relatives
Family history of cancer at atypical 
sites and age at diagnosis of 
affected relatives
636 Br48 Br69;Ov69(M), Br30(MA) CLL46(B), Thy;Lu50(MU), 
PSU50(MU), Pan44(MC)
762 Ov48;Ut48 BilBr55-57(S), Br65(PA), Br62(PC), 
Br45(PC), Br40(PC)
Lar60(PC), Hod/Lym55(PC), 
BD46(PC)
859 Br27 Br37(S), Br50(PA) Pro55(PU), PSU63(PU)
937 Br33 Br47(S), Br44(PC), Br45(PC), 
Br39(PC), Br53(PC)
PSU61(F), Lu50(S),
1429 Br54 Br40;Bone46(S), Br44(MA), 
Br50(MA), Br52(MGM)
Pan66(M), PSU44(N), Co59(MU), 
Co(MU)
1430 Ov68;Pel72 Br67(S), Leu76(S)
1441 Br52 Br49(MA), Br69(MA), Br68(MA), 
Ov50(MA), Br50(MA), 
Br58(MGM)
Lu64(MU), Brn41(MC)
1448 Ov76 Ov71(S), Br50(S), Br46(N)
1450 Br45;Lu80 Br35(N) Cx25(GD), Bone;Leu14(N), 
PSU47(N)
1454 Br26;Co44 Br45(PA), Br52(MA), Br34(MC) Pro54(F), Mouth80(M), Lu62(PU), 
Pro73(PU), St58(PGF)
1458 Br45;FT45 Br52(S), Br52(PC), Br55(MC), 
Br53(MC)
Pro74(PU), Co43(PC), Co54(PC), 
Co54(PC), PSU60(PGF), 
Co40(MC), Cx43(MC)
Cancer site or type followed by age of diagnosis (if known): Breast (Br), bilateral breast (BilBr), ovarian (Ov), Uterus (Ut), prostate (Pro), colon 
(Co), chronic lymphoid leukemia (CLL), Leukemia (Leu), Lung (Lu), Pancreas (Pan), Brain (Brn), Larynx (Lar), Hodgkin's lymphoma (Hod/Lym), Bile 
duct (BD), Pelvic (Pel), Intestinal (In), Stomach (St), Cervix (Cx), Fallopian Tube (FT) and Primary site unknown (PSU). Affected relatives in 
parentheses: sister (S), brother (B), mother (M), father (F), daughter (D), granddaughter (GD), paternal aunt (PA), paternal uncle (PU), paternal 
cousin (PC), maternal aunt (MA), maternal uncle (MU), maternal cousin (MC), maternal grandmother (MGM), paternal grandfather (PGF) and niece 
(N). Multiple cancers in an individual are denoted by semicolon.Page 3 of 7
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taining BRCA2 (Table 2). Haplotypes were phased for all
markers for only five of the eleven families (636, 762,
1441, 1454 and 1458) due to limitations of reagents from
family members or inability to phase all genotypes based
on non-informativity of markers (Table 2). Based on the
results from these families, two haplotypes were observed,
7-3-9-3 – [3/4]-7, which varied for the D13S1701 alleles.
All mutation carriers of unphased genotypes harboured
alleles consistent with either haplotype. The disease asso-
ciated alleles in 3398delAAAAG carriers were distinct for
markers D13S260, D13S1698, D13S169, and D13S171
when compared with those found to segregate with carri-
ers of the 8765delAG mutation [6], the most common
BRCA2 mutation reported in French Canadian cancer
families (Table 2). The most common allele(s) in unaf-
fected individuals for four of the six markers tested were
those associated with 3398delAAAAG (Table 3). Although
the alleles associated with the recurrent mutation are fre-
quent in the population (Table 3), neither mutation-asso-
ciated haplotype was plausible in reconstructed
haplotypes of 47 French Canadians unaffected with can-
cer. Furthermore, the D13S1697 disease segregating allele,
situated 0.2 cM immediately proximal to BRCA2, was not
the most common allele in the unaffected French Canadi-
ans. Under the assumption of linkage disequilibrium, the
frequency of either haplotype associated with the
3398delAAAAG mutation was estimated at 0.001. This
result suggest that the 3398delAAAAG mutation is not car-
ried on haplotype comprised of the most common alleles
in the French Canadian population and provides support
for the notion that the haplotypes of the mutation carriers
are identical by descent in the French Canadian popula-
tion.
In order to establish if a recombination event could
account for the differences in the haplotypes, we geno-
typed an additional polymorphic microsatellite repeat
marker, D13S1695, which is situated approximately 1.4
cM from the 5' end of BRCA2 [11,12]. Genotypes of
phased alleles flanking BRCA2 in mutation carriers would
not favour a genetic recombination event. The variance in
allele size of one tetranucleotide repeat unit within the
D13S1701 allele, may have been due to a mutation caused
by slippage during DNA replication of this repeat
sequence. While the frequency of DNA replication errors
in repeat sequences and the affect of repeat unit size are
not known, studies have shown a positive correlation
between repeat length and mutation rates [16]. Without
further genetic analysis it was not possible to determine if
D13S1701 exhibits a higher mutation frequency than
other markers in the BRCA2 region or that the mutation
occurred early in the development of the French Canadian
population. The later possibility is suggested by the obser-
Table 2: Genotypes of an index case from 3398delAAAAG mutation carrier families.
Family 
Number
Index case 
(mutation 
carrier)
Alleles
D13S260 D13S1699 D13S1698 D13S1697 D13S1701 D13S171 D13S1695
636* t N2254 7 9 3 1 9 6 3 2 4 4 7 9 5 3
762* t S359 7 7 3 4 9 9 3 2 5 3 7 2 5 5
859* t N2865 7,4 3,6 9,8 3,1 4,6 7,2 5,4
937* t S386-2 7 7 3,4 9,11 3,2 4,6 7,2 5 5
1450 t S1376 7 5 3 4 9,11 3,2 4,2 7 2 5 3
1448 t S1054 7,3 3 4 9 9 3 2 4 3 7,2 5 4
1429 N5445 7,4 3 3 9,11 3,2 4,3 7 7 5,2
1430 N5446 7 7 3,4 9 9 3,2 2,3 7,5 5 5
1441 t S1908 7 7 3 4 9 9 3,2 4 3 7 2 5 9
1454 t S922 7 8 3 3 9 3 3 3 4 4 7 9 5 5
1458 t S2160 7 7 3 4 9 3 3 2 4 2 7 9 5 3
Mutation carriers Deduced haplotype
3398delAAAAG 7 3 9 3 3,4 7 5
8765delAG 4 3 11 2 4 9 -
Families reported previously [10] (*). The 3398delAAAAG associated alleles are in boldface type, haplotypes not segregating with the BRCA2 
mutant alleles are in italics, and genotypes of unphased alleles are separated by a comma. Phase was established by comparing genotypes of two to 
nine family members per family where additional members were available for analysist. Alleles common in the French Canadian population reported 
previously [6]. The physical distance between D13S260 to D13S1695 is about 3.5 Mb [15]; BRCA2 is located between D13S1697 and D13S701 [11] 
The intermarker distances are D13S260 – 1.0 cM – D13S1699 – 0.7 cM – D13S1698 – 0.6 cM – D13S1697 – 0.2 cM – BRCA2 – 0.5 cM – D13S1701 
– 0.6 cM – D13S171 – 0.3 cM – D13S1695 [12].Page 4 of 7
(page number not for citation purposes)
BMC Medical Genetics 2006, 7:23 http://www.biomedcentral.com/1471-2350/7/23vation that both haplotypes could be associated with
3398delAAAAG in more than one unrelated mutation car-
rier.
The 3398delAAAAG mutation has been previously
reported eight times in the Breast Cancer Information
Core Database [17], where all carriers were either of West-
ern European or French Canadian descent [18]. Presently
it is not known if the French Canadian carriers reported in
this database are those identified in our hereditary cancer
clinics and thus related to members of the families in the
present study. The mutation was identified in 1 of 60
(1.7%) women with breast cancer diagnosed before 41
years of age and none in the independently ascertained
series of 127 women with breast cancer diagnosed before
80 years of age, and 1 of 80 (1.3%) women with ovarian
cancer. The frequency of mutation carriers in these series
is keeping with the observation that four of 169 (2.4%)
high-risk breast and/or ovarian cancer families of French
Canadian descent harboured this mutation in that this
recurrent mutation is not as common as the 4446C>T in
BRCA1 and 6085G>T and 8765delAG in BRCA2 in this
population [7-10]. The mutation-positive carriers were
represented by families 636 and 859 (Table 2) and thus
mutation-positive carriers in these families harbour geno-
types in common with other carriers of this mutation.
Carriers of this mutation in our series of eleven families
appear not to share a recent relationship based on inspec-
tion of pedigrees, although all families cite the Montreal
region and Central Quebec as place of origin of grandpar-
ents, unlike carriers of either the 8765delAG or 4446C>T
BRCA mutations which reported grandparental origins in
various regions of Quebec [1]. Thus it would be interest-
ing to compare haplotypes of all carriers of
3398delAAAAG mutation to determine those in the
French Canadian population share common ancestry
with Western Europeans.
The 3398delAAAAG mutation is located within the Ovar-
ian Cancer Cluster Region (OCCR) in exon 11 of BRCA2,
which has been associated with increased risk for ovarian
cancer in breast cancer families [19]. Although the pres-
ence of at least one ovarian cancer in high risk French
Canadian families is a strong predictor of a BRCA1 muta-
tion [1], four of the nine mutation carrier high risk fami-
lies (families 636, 762, 1441, and 1448) in the present
study contained at least one case of ovarian cancer (Table
1). One of these families, number 1448, also had two
cases of ovarian cancer. The index case for testing in family
1430 also had ovarian cancer, although this family would
not have been selected for mutation analysis based on our
inclusion criteria for mutation screening [1,10]. As
observed in our previous studies of French Canadian can-
cer families [10], with one exception in family 762, the
age of diagnosis of ovarian cancer was higher than the
mean age of diagnosis of ovarian cancer (age 56 years) in
the Canadian population [20]. This is particularly evident
in family 1448 where both cases of ovarian cancer were
diagnosed after age 70 years (Table 1). The index case in
Family 1458 diagnosed with breast cancer at age 45 years
was also diagnosed with a primary cancer of the fallopian
tube, (Table 1), a type of gynecological cancer which
shares many clinicopathologic features in common with
epithelial ovarian cancers. Germline BRCA mutations
have been reported in women with fallopian tube cancers
supporting the notion that these cancers share a common
molecular pathogenesis with ovarian cancers [21]. Taken
together, five of the nine high risk families contain cases
Table 3: Allele frequencies in non-carriers or French Canadians unaffected with cancer and carriers of 3398delAAAAG mutation.
Allele Marker (number of subjects)
D13S260 D13S1699 D13S1698 D13S1697 D13S1701 D13S171
NC (45) C (11) NC (43) C (11) NC (51) C (11) NC (35) C (11) NC (41) C (11) NC (41) C (11)
0 - - - - - - - - - - - -
1 - - 0.05 0.05 - - 0.01 0.05 0.01 - 0.02 -
2 0.02 - 0.02 - 0.02 - 0.74 0.41 0.07 0.14 0.40 0.27
3 0.19 0.05 0.62 0.59 0.05 0.09 0.24 0.55 0.22 0.23 0.02 -
4 0.08 0.09 0.27 0.32 0.03 - - - 0.23 0.50 - -
5 0.09 0.05 0.02 - 0.02 - - - 0.18 0.05 0.01 0.05
6 0.06 - 0.01 0.05 0.08 0.05 - - 0.21 0.09 - -
7 0.32 0.73 - - 0.04 - - - 0.06 - 0.33 0.55
8 0.11 0.05 - - 0.02 0.05 - - - - - -
9 0.12 0.05 - - 0.40 0.68 - - 0.01 - 0.21 0.14
10 0.01 - - - 0.04 - - - - - - -
11 - - 0.01 - 0.30 0.14 - - - - - -
12 - - - - - - - - - - - -
13 - - - - - - - - - - - -
The figures in bold type show the most common allele. Alleles in italics associated with 3398delAAAAG mutation. NC and C refer to non-carriers 
and carriers of this mutation, respectively.Page 5 of 7
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association with mutations in the OCCR region and ovar-
ian cancer risk in the French Canadian high-risk popula-
tion is not known, the proportion of high-risk
3398delAAAAG mutation-positive families with at least
one case of ovarian cancer is not significant different from
those harbouring the 6503delTT mutation (20% (2/10))
located within the OCCR region and the 8765delAG
mutation (29% (5/17)) located outside of the OCCR
region, the other two recurrent BRCA2 mutations in the
French Canadian population [10].
Conclusion
This study provides further evidence towards common
origins of the BRCA mutations in the French Canadian
population of Quebec and further rationalizes a targeted
screening of recurrent mutations in this population before
large-scale mutation analyses are performed.
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